Updated on 7 January 2014
China has said that the suspension on production for key suppliers of Hepatitis B vaccine would continue
Singapore: Concluding an elaborate probe that started late last year, China has now said that the hepatitis B vaccines were not the cause of infant deaths.
It said that the nine deaths in infants were not caused by the hepatitis B virus inoculations, even as the suspension on production for key suppliers would continue.
The year started for the country's top three manufacturers with a suspension of manufacturing of their hepatitis B vaccines in the wake of the deaths. For more than a week, this move has sparked debate about a shortage that could come up following this.
Meanwhile, since Beijing Tiantan Biological Products, Shenzhen Kangtai Biological Products and Dalian Hissen Bio-Pharm have not been certified as meeting China's 2011 Good Manufacturing Practice (GMP) standards.
Reports pointed out that the new GMP rules place greater emphasis on the use of effective quality control system by pharmaceutical companies and introduce new standards on supplier audits, change control, raw material procurement and standard operating procedures.